Info
upfront treatment of acute myelogenous leukemia (AML)
什麼是七加三?
FLT3-ITD/TKD mutation
- 7+3+ midostaurin 👉 ❌ FLT3
- FLT3
Core-binding factor
t(8;21) or inv(16): 7+3 ± GO是CD多少的inhitbitor? (CD33)
2° AML or w/ MDS-related changes
- CPX-351 (liposomal Ara-C & daunorubicin)
- <60 y: 7+3 (high-dose daunorubicin 90 mg/m2);
-
60 y: dauno 60 mg/m2
Regimens for unfit
(may include age ≥75 y or < 75y w/ ECOG ≥3 or severe cardiac or pulmonary comorbidity; Leukemia 2013;27:997)
- Azacitadine + venetoclax (Bcl2 inhibitor) (NEJM 2020;383:617)
IDH1_IDH2 mutation: ivosidenib or enasedinib